新型前列腺癌药物在新临床试验中显示前景
Prostate cancer drug shows promise in new clinical trial
一项由耶鲁大学领导的临床试验显示,新型前列腺癌药物 Bavdegalutamide 在减少肿瘤活动和缓解疼痛方面对晚期去势抵抗性前列腺癌患者有积极效果。该药物属于第一类 PROTAC 药物,可加速雄激素受体的蛋白降解,对不同突变类型的前列腺癌有不同疗效。
报道了一种新型前列腺癌药物在临床试验中的初步积极结果,可为精准治疗提供新思路。
In a recent Yale-led clinical trial, a new type of prostate cancer drug showed promising results in reducing tumor activity and pain for patients with metastatic prostate cancer.
"This is a first-in-class drug for prostate cancer," says Daniel Petrylak, professor of medicine (oncology and hematology) at Yale School of Medicine and senior author of the study, published Oct. 9 in the Journal of Clinical Oncology.
Patients in the phase 1/phase 2 clinical trial were diagnosed and previously treated for metastatic castration-resistant prostate cancer (mCRPC), an incurable, lethal form of the disease. Oncologists typically treat prostate cancer by starving it of testosterone, which halts growth for a time. But with mCRPC, the cancer continues to grow even with limited testosterone.
"More than 35,000 men will die from mCRPC in the United States this year," says Petrylak, a member of Yale Cancer Center. "It's the most advanced form of prostate cancer."
Bavdegalutamide is the first PROTAC androgen receptor degrader to be clinically tested. PROTACs are a new class of cancer drug that use proteolysis, the natural process wherein a cell breaks down proteins to recycle the materials, to degrade cancers. PROTACs were pioneered by Yale researcher Craig Crews, including the first PROTAC approved by the U.S. Food and Drug Administration for use in breast cancer.
Bavdegalutamide was designed to treat mCRPC by bypassing its resistance to other hormone therapies. "Bavdegalutamide takes your own natural protein degradation system, and it accelerates the process for the androgen receptor. The drug degrades the receptors for testosterone, which control prostate cancer growth," says Petrylak.
In phase 1 of the trial, the researchers found that a 420-milligram daily dose was safe for patients who had already been treated for mCRPC. In phase 2, they evaluated the drug's effectiveness. The team of researchers and clinicians measured prostate-specific antigen, which is the hallmark of mCRPC, before and after administering the drug.
"There was a decrease in prostate-specific antigen. We also saw regressions in soft tissue lesions and improvements in pain," says Petrylak. "These are the parameters that indicate a positive response."
The research collaborators also studied the effect that bavdegalutamide had on prostate cancers with different mutations. In cancers with what are known as T878 and/or H875 mutations of androgen receptors, bavdegalutamide led to a greater reduction of prostate-specific antigen. The study's authors point to this result as an indicator of PROTAC drugs being used as precision medicine.
The researchers and clinician collaborators are currently testing a second PROTAC, called ARV 766, in phase 1 and phase 2 clinical trials. This drug is active against a broader spectrum of androgen receptor mutations than ARV-110.
Publication details
Xin Gao et al., Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer, Journal of Clinical Oncology (2026). DOI: 10.1200/jco-25-02995
Journal information: Journal of Clinical Oncology
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Prostate cancer drug shows promise in new clinical trial (2026, November 4) retrieved 4 November 2026 from https://medicalxpress.com/news/2026-11-prostate-cancer-drug-clinical-trial.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com